A study in the Journal of the American Academy of Dermatology examined the incidence of psoriasis according to body mass index.
A recent study investigated apremilast use for psoriasis during COVID-19 infection.
The FDA grants Priority Review for spesolimab (BI655130; Boehringer Ingelheim) as a treatment for generalized pustular psoriasis.
The New England Journal of Medicine has published the clinical trial data from the PSOARING 1 and PSOARING 2 studies on tapinarof treatment for plaque psoriasis.
In this exclusive video interview, James Q Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the headlines around the treatments.
In a video for Dermatology Times®, Mark Lebwohl, MD, details how to match patients with the right psoriasis treatment for their specific needs.
An article published in the Journal of Investigative Dermatology examined genetic, environmental triggers, immunology, pathophysiology, and precision medicine in psoriasis.
A phase 3 study evaluated apremilast as a treatment for patients with mild to moderate psoriasis.
In this video interview, Mark Lebwohl, MD, explains why topicals for inflammatory conditions are vital for treatment.
In this episode, we dive into the background of the “The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas.” Adam Friedman, MD, and Misty Eleryan MD, MS, describe their process to creating this new dermatologic resource.